GlassScriptPhysician profile
Basava P Kunamneni
NPI 1376558239
$531.96
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $139.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $79.80 | 2019 | |
| Amgen INC. | $78.51 | 2019 | |
| Boston Scientific Corporation | $59.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.82 | 2019 | |
| Vifor Pharma, INC. | $33.15 | 2019 | |
| Portola Pharmaceuticals, LLC | $25.87 | 2019 | |
| Astellas Pharma US INC | $24.06 | 2019 | |
| Acadia Pharmaceuticals INC | $21.55 | 2019 | |
| Abbvie INC. | $15.44 | 2019 | |
| Akebia Therapeutics INC | $14.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basava Kunamneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.